The untapped potential of Gallium 68-PET: the next wave of ⁶⁸Ga-agents

Appl Radiat Isot. 2013 Jun:76:14-23. doi: 10.1016/j.apradiso.2012.10.014. Epub 2012 Oct 29.

Abstract

(68)Gallium-PET ((68)Ga-PET) agents have significant clinical promise. The radionuclide can be produced from a (68)Ge/(68)Ga generator on site and is a convenient alternative to cyclotron-based PET isotopes. The short half-life of (68)Ga permits imaging applications with sufficient radioactivity while maintaining patient dose to an acceptable level. Furthermore, due to superior resolution, (68)Ga-PET agents have the ability to replace current SPECT agents in many applications. This article outlines the upcoming agents and challenges faced during the translational development of (68)Ga agents.

MeSH terms

  • Amine Oxidase (Copper-Containing) / metabolism
  • Cell Adhesion Molecules / metabolism
  • Gallium Radioisotopes*
  • Glucagon-Like Peptide 1 / metabolism
  • Half-Life
  • Insulinoma / diagnostic imaging
  • Neuroendocrine Tumors / diagnostic imaging
  • Octreotide / analogs & derivatives
  • Oligopeptides / metabolism
  • Organometallic Compounds
  • Positron-Emission Tomography / methods*
  • Radionuclide Generators
  • Radiopharmaceuticals*
  • Receptors, Bombesin / metabolism
  • Receptors, Somatostatin / metabolism
  • Single-Domain Antibodies / metabolism
  • Somatostatin / analogs & derivatives
  • Somatostatin / metabolism
  • Vascular Endothelial Growth Factor A / metabolism

Substances

  • Cell Adhesion Molecules
  • Gallium Radioisotopes
  • Oligopeptides
  • Organometallic Compounds
  • Radiopharmaceuticals
  • Receptors, Bombesin
  • Receptors, Somatostatin
  • Single-Domain Antibodies
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Somatostatin
  • arginyl-glycyl-aspartic acid
  • Glucagon-Like Peptide 1
  • gallium Ga 68 dotatate
  • AOC3 protein, human
  • Amine Oxidase (Copper-Containing)
  • Octreotide
  • Edotreotide